SV investment has resulted in the approval of 24 novel therapeutics
SV News
- 15 April 2021Portfolio NewsSutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck
15 April 2021Portfolio NewsSitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer
15 April 2021Portfolio NewsAlchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics
12 April 2021Portfolio NewsXilio Therapeutics Strengthens Management Team with R&D Leadership Appointments
7 April 2021Portfolio NewsArtios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies- 3 April 2021SV NewsUK vaccine supremo Kate Bingham: ‘The bickering needs to stop’
- 30 March 2021Portfolio NewsPionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development
- 16 March 2021Portfolio NewsAlchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease
- 24 February 2021Portfolio NewsXilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline
- 11 February 2021Portfolio NewsArtios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients
26 January 2021Portfolio NewsBicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data of Tumor-Targeted Immune Cell Agonists (TICAs™) in the Journal for ImmunoTherapy of Cancer- 12 January 2021Portfolio NewsArtios Pharma Appoints Abid Ansari as Chief Financial Officer
